(Q51006230)

26 March 2018

title

Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer. (English)

1 reference

26 March 2018

author name string

Yiting Geng

1

1 reference

26 March 2018

Xiaofeng Chen

2

1 reference

26 March 2018

Jinrong Qiu

3

1 reference

26 March 2018

Yue Zhou

4

1 reference

26 March 2018

Jian Wang

5

1 reference

26 March 2018

Lingxiang Liu

6

1 reference

26 March 2018

Yongfeng Shao

7

1 reference

26 March 2018

Yongmei Yin

8

1 reference

26 March 2018

publication date

10 May 2013

1 reference

26 March 2018

number of pages

9

1 reference

International Journal of Clinical Oncology

inferred from page(s)

published in

1 reference

26 March 2018

volume

19

1 reference

26 March 2018

issue

2

1 reference

26 March 2018

page(s)

303-311

1 reference

26 March 2018

https://scigraph.springernature.com/pub.10.1007/s10147-013-0542-9

exact match

0 references

cites work

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

The ErbB receptors and their ligands in cancer: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Antitumor activity of HER-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

HER-2/neu expression in primary and metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

HER-2 amplification is highly homogenous in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Japanese Classification of Gastric Carcinoma - 2nd English Edition -

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

HER2 status of gastric carcinoma and corresponding lymph node metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-013-0542-9

Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.

21 January 2018

1 reference

12 December 2020

c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems

1 reference

12 December 2020

Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

1 reference

12 December 2020

Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study

1 reference

12 December 2020

Ratio of metastatic lymph nodes: impact on staging and survival of gastric cancer

1 reference

12 December 2020

Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study)

1 reference

12 December 2020

Comparative study on overexpression of HER2/neu and HER3 in gastric cancer

1 reference

12 December 2020

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

1 reference

12 December 2020

Angiogenesis and c-erbB-2 (HER2/neu) overexpression status in primary breast cancer patients: an analysis of 158 needle core biopsies

1 reference

12 December 2020

Correlation between expression of leptin and clinicopathological features and prognosis in patients with gastric cancer

1 reference

12 December 2020

HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy

1 reference

12 December 2020

The prognostic value of N-ratio in patients with gastric cancer: Validation in a large, multicenter series

1 reference

12 December 2020

Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

1 reference

12 December 2020

10.1007/S10147-013-0542-9

Identifiers

DOI

1 reference

26 March 2018

PubMed ID

23660785

1 reference

26 March 2018